Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125923471 | 12592347 | 1 | I | 20160712 | 20160726 | 20160726 | EXP | JP-CIPLA LTD.-2016JP09714 | CIPLA | SHIMADA M, NAGAO S, FUJIWARA K, TAKESHIMA N, TAKIZAWA K, SHOJI T, ET AL. NEOADJUVANT CHEMOTHERAPY WITH DOCETAXEL AND CARBOPLATIN FOLLOWED BY RADICAL HYSTERECTOMY FOR STAGE IB2, IIA2, AND IIB PATIENTS WITH NON-SQUAMOUS CELL CARCINOMA OF THE UTERINE CERVIX. INT J CLIN ONCOL. 2016 | 0.00 | Y | 0.00000 | 20160726 | OT | JP | JP |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125923471 | 12592347 | 1 | PS | CARBOPLATIN. | CARBOPLATIN | 1 | Intravenous (not otherwise specified) | AUC 6, FOR 2 HR, EVERY 21 DAYS | 0 | INFUSION | |||||||||
125923471 | 12592347 | 2 | SS | DOCETAXEL. | DOCETAXEL | 1 | Intravenous (not otherwise specified) | 60 MG/M2, FOR 1 HR, EVERY 21 DAYS | 0 | 60 | MG/M**2 | INFUSION |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125923471 | 12592347 | 1 | Cervix carcinoma |
125923471 | 12592347 | 2 | Cervix carcinoma |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
125923471 | 12592347 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125923471 | 12592347 | Disease progression |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |